BioZorbRecalls & reported problems across all models

We found 9 models of BioZorb by Hologic, Inc. in the FDA's device registry (GUDID). Together they are named in 326 adverse event reports in the FDA's MAUDE database, received between May 11, 2022 and Sep 30, 2026 — classified as 314 injuries, 12 malfunctions.

The most frequently reported specific device problem is “Fracture” (21 reports).

3 FDA recall records name at least one of these models by its device identifier, 3 still open.

Reports come from manufacturers, hospitals and patients and are not verified by the FDA. A report does not prove the device caused the event. Widely used products collect more reports, so totals can't be used to compare products or estimate failure rates. Only reports that name a model's exact device identifier are counted. What reports can and can't tell you · How this data works

BioZorb recalls

FDA recall records that name at least one of these models by its device identifier, newest first. Each recall usually covers specific models or lots, so check the details.

1. Oct 10, 2024Open, Classified

   Firm received reports of adverse events/complications that include serious injuries, such as pain, infection, rash, device migration, device erosion, seroma, and discomfort.

   Z-0328-2025 · Root cause: Device Design · names 9 of these models · Recall details · FDA record ↗

2. Mar 13, 2024Open, Classified

   Safety Information: Complaints describe complications/adverse events that include pain, infection, rash, device migration, device erosion, seroma, discomfort, or other complications from feeling the device in the breast, and the need for additional medical treatment to remove the device

   Z-1733-2024 · Root cause: Unknown/Undetermined by firm · names 9 of these models · Recall details · FDA record ↗

3. Aug 9, 2022Open, Classified

   Hologic BioZorb LP Marker, (Product number F0221), lot number 22A0RL, contained removable labels with an expiration date that indicated the product had already expired. The expiration date on the removable label is actually manufacturing date, and it's different from the one on the shelf box label, which is the correct expiration date.

   Z-1858-2022 · Root cause: Incorrect or no expiration date · Recall details · FDA record ↗

Most reported BioZorb problems

BioZorb models

9 models, most reported first. Each model has its own page with its reports, recalls and device details.

• BioZorb F0202

  MARKER, RADIOGRAPHIC, IMPLANTABLE
  2 recalls192 reports
• BioZorb F0221

  MARKER, RADIOGRAPHIC, IMPLANTABLE
  3 recalls15 reports
• BioZorb F0203

  MARKER, RADIOGRAPHIC, IMPLANTABLE
  2 recalls51 reports
• BioZorb F0303

  MARKER, RADIOGRAPHIC, IMPLANTABLE
  2 recalls19 reports
• BioZorb F0304

  MARKER, RADIOGRAPHIC, IMPLANTABLE
  2 recalls19 reports
• BioZorb F0231

  MARKER, RADIOGRAPHIC, IMPLANTABLE
  2 recalls19 reports
• BioZorb F0404

  MARKER, RADIOGRAPHIC, IMPLANTABLE
  2 recalls6 reports
• BioZorb F0331

  MARKER, RADIOGRAPHIC, IMPLANTABLE
  2 recalls4 reports
• BioZorb F0405

  MARKER, RADIOGRAPHIC, IMPLANTABLE
  2 recalls1 report

Recent BioZorb adverse event reports

The 15 most recent reports across all models, in the reporter's own words as published by the FDA.

• InjurySep 30, 2026Adverse Event Without Identified Device or Use Problem

  Patient problems: Breast Discomfort/Pain; Breast Mass

  MAUDE report 50949203 ↗
• InjuryAug 6, 2026Adverse Event Without Identified Device or Use Problem

  Hologic has received correspondence arising from litigation. The litigation alleges that a patient of undisclosed age, on (b)(6) 2018, underwent a right breast lumpectomy with BioZorb placement and a simultaneous left breast lift. Shortly thereafter, the patient was diagnosed with ductal carcinoma in her right breast, and on (b)(6) 2018, she underwent re-excision with BioZorb replacement. Following the surgeries, the patient developed a painful, long-term seroma in her right breast, along with persistent pain and tenderness at the implant site, nodule formation, and lymph node swelling that continued for years. Patient required needle drainage and was told she was experiencing "delayed healing." Patient was later informed that Hologic had extended the expected resorption timeline for BioZorb - potentially up to two years, well beyond what she had originally been told. Patient has since suffered years of chronic pain, lymph node swelling, and an inability to wear a bra or swimsuit for any meaningful length of time without significant discomfort, requiring ongoing licensed massage therapy and lymph drainage at her own expense. In (b)(6) 2026, the Patient observed new, deeper dimpling

  Patient problems: Breast Discomfort/Pain; Breast Mass; Deformity/ Disfigurement; Impaired Healing; Nodule; Seroma; Swelling/ Edema; Swollen Lymph Nodes/Glands

  MAUDE report 50161479 ↗
• InjuryJul 27, 2026Adverse Event Without Identified Device or Use Problem

  Hologic has received correspondence arising from litigation. The litigation alleges that a 55 year old patient was implanted on (b)(6) 2020 with a BioZorb marker following a surgical procedure for a Left breast lumpectomy. The patient underwent the prescribed Radiation and Endocrine therapy. On (b)(6) 2023 the patient presented at a medical consultation with a painful persistent palpable mass in the left breast. The pain increased with movement and when pressed along the implant site incision line. The patient indicated the symptoms were persistent during the last 3 years. The MD discussed with the patient the possibility to schedule an explanation surgery and the patient agreed. On (b)(6) 2023 the patient underwent a surgical procedure for left breast mass excision, together with the BioZorb implant which was included in the breast mass. No other relevant Information was provided.

  Patient problems: Breast Discomfort/Pain; Breast Mass; Limb Pain

  MAUDE report 50037276 ↗
• InjuryMay 25, 2026Adverse Event Without Identified Device or Use Problem

  HOLOGIC HAS RECEIVED CORRESPONDENCE ARISING FROM LITIGATION. THE LITIGATION ALLEGES THAT A 53-YEAR-OLD PATIENT WAS IMPLANTED ON (B)(6) 2024 WITH A BIOZORB MARKER FOLLOWING A SURGICAL PROCEDURE FOR A RIGHT BREAST LUMPECTOMY. ON (B)(6) 2025 PATIENT PRESENTED WITH CONCERNS RELATED TO THE RIGHT BREAST TISSUE PAIN ASKING TO BE EVALUATED FOR INFECTION. PATIENT ENDORSED PRESENCE OF RIGHT BREAST PAIN SINCE (B)(6) 2024. ON (B)(6) 2025 THE PATIENT UNDERWENT A SURGICAL INTERVENTION FOR BIOZORB REMOVAL. THE IMPLANT WAS FOUND PARTIALLY ABSORBED, AND IN 2 SEPARATE PIECES WHICH WERE REMOVED FROM THE SURROUNDING BREAST TISSUE. NO OTHER RELEVANT INFORMATION WAS PROVIDED. THIS REPORT IS BEING SUBMITTED PURSUANT TO 21 CFR PART 803 BASED ON INFORMATION MADE AVAILABLE TO HOLOGIC THROUGH LITIGATION. CONSISTENT WITH 21 CFR 803.16, THE SUBMISSION OF THIS REPORT IS NOT INTENDED, AND SHALL NOT BE CONSTRUED, AS AN ADMISSION, ACKNOWLEDGMENT, OR CONFIRMATION BY HOLOGIC THAT THE DEVICE CAUSED OR CONTRIBUTED TO THE REPORTABLE EVENT.

  Patient problems: Breast Discomfort/Pain

  MAUDE report 25271156 ↗
• InjuryMay 19, 2026Adverse Event Without Identified Device or Use Problem

  HOLOGIC HAS RECEIVED CORRESPONDENCE ARISING FROM LITIGATION. THE LITIGATION ALLEGES THAT A 67-YEAR-OLD PATIENT WAS IMPLANTED ON (B)(6) 2023 WITH A BIOZORB MARKER FOLLOWING A SURGICAL PROCEDURE FOR A LEFT BREAST LUMPECTOMY. ON (B)(6) 2024 PATIENT PRESENTED WITH CONTINUED PAIN AT THE SITE OF THE IMPLANT AND SHE DESIRES THE REMOVAL OF THE BIOZORB DEVICE. ON THE SAME DAY THE PATIENT UNDERWENT A SURGICAL PROCEDURE FOR BIOZORB REMOVAL. NO OTHER RELEVANT INFORMATION WAS PROVIDED. THIS REPORT IS BEING SUBMITTED PURSUANT TO 21 CFR PART 803 BASED ON INFORMATION MADE AVAILABLE TO HOLOGIC THROUGH LITIGATION. CONSISTENT WITH 21 CFR 803.16, THE SUBMISSION OF THIS REPORT IS NOT INTENDED, AND SHALL NOT BE CONSTRUED, AS AN ADMISSION, ACKNOWLEDGMENT, OR CONFIRMATION BY HOLOGIC THAT THE DEVICE CAUSED OR CONTRIBUTED TO THE REPORTABLE EVENT.

  Patient problems: Breast Discomfort/Pain

  MAUDE report 25219655 ↗
• InjuryMay 13, 2026Adverse Event Without Identified Device or Use Problem

  HOLOGIC HAS RECEIVED CORRESPONDENCE ARISING FROM LITIGATION. THE LITIGATION ALLEGES THAT A 68-YEAR-OLD PATIENT WAS IMPLANTED ON (B)(6) 2023 WITH A BIOZORB MARKER FOLLOWING A SURGICAL PROCEDURE FOR A RIGHT BREAST LUMPECTOMY. ON (B)(6) 2024, THE PATIENT REPORTED FOCAL PAIN AT THE RIGHT BREAST LEVEL. NO OTHER RELEVANT INFORMATION WAS PROVIDED. THIS REPORT IS BEING SUBMITTED PURSUANT TO 21 CFR PART 803 BASED ON INFORMATION MADE AVAILABLE TO HOLOGIC THROUGH LITIGATION. CONSISTENT WITH 21 CFR 803.16, THE SUBMISSION OF THIS REPORT IS NOT INTENDED, AND SHALL NOT BE CONSTRUED, AS AN ADMISSION, ACKNOWLEDGMENT, OR CONFIRMATION BY HOLOGIC THAT THE DEVICE CAUSED OR CONTRIBUTED TO THE REPORTABLE EVENT.

  Patient problems: Breast Discomfort/Pain

  MAUDE report 25159208 ↗
• InjuryMay 12, 2026Adverse Event Without Identified Device or Use Problem

  HOLOGIC HAS RECEIVED CORRESPONDENCE ARISING FROM LITIGATION. THE LITIGATION ALLEGES THAT A 48-YEAR-OLD PATIENT WAS IMPLANTED ON (B)(6), 2022 WITH A BIOZORB MARKER FOLLOWING A SURGICAL PROCEDURE FOR A LEFT BREAST LUMPECTOMY. ON (B)(6) 2024 THE PATIENT PRESENTED WITH COMPLAINTS OF BIOZORB MARKER FAILING TO DISSOLVE AND IT BOTHERED THE PATIENT. PATIENT REQUESTED TO HAVE THE BIOZORB MARKER REMOVED. IT WAS REMOVED ON THE SAME DATE WITH THE MENTION THAT AN INFECTION WAS NOT PRESENT AT THE DATE OF REMOVAL. NO OTHER RELEVANT INFORMATION WAS PROVIDED. THIS REPORT IS BEING SUBMITTED PURSUANT TO 21 CFR PART 803 BASED ON INFORMATION MADE AVAILABLE TO HOLOGIC THROUGH LITIGATION. CONSISTENT WITH 21 CFR 803.16, THE SUBMISSION OF THIS REPORT IS NOT INTENDED, AND SHALL NOT BE CONSTRUED, AS AN ADMISSION, ACKNOWLEDGMENT, OR CONFIRMATION BY HOLOGIC THAT THE DEVICE CAUSED OR CONTRIBUTED TO THE REPORTABLE EVENT.

  Patient problems: Breast Discomfort/Pain; Breast Mass

  MAUDE report 25153628 ↗
• InjuryMar 16, 2026Adverse Event Without Identified Device or Use Problem

  HOLOGIC HAS RECEIVED CORRESPONDENCE ARISING FROM LITIGATION. THE LITIGATION ALLEGES THAT A PATIENT UNDERWENT A RIGHT BREAST LUMPECTOMY WITH BIOZORB PLACEMENT ON (B)(6) 2023. IT IS FURTHER ALLEGED THAT IN THE MONTHS FOLLOWING THE LUMPECTOMY, THE PATIENT DEVELOPED INTERMITTENT RIGHT BREAST AND AXILLARY DISCOMFORT. IT WAS REPORTED IN THE LITIGATION THAT "IMAGING IN (B)(6) 2024 SHOWED ONLY SCAR TISSUE AND A SEROMA WITHOUT EVIDENCE OF RECURRENT DISEASE. HOWEVER, BY (B)(6) 2024, EXAMINATION REVEALED A FIRM AREA WITH ASSOCIATED DIMPLING IN THE REGION OF THE BIOZORB." ACCORDING TO THE LITIGATION, THE PATIENT REPORTED A "FIRM, PAINFUL MASS AT THE LUMPECTOMY SITE AND ONGOING TENDERNESS" TO HER CARE TEAM. IT IS REPORTED THAT ON (B)(6) 2025, THE PATIENT UNDERWENT RIGHT BREAST LUMPECTOMY WITH REMOVAL OF THE BIOZORB. THIS REPORT IS BEING SUBMITTED PURSUANT TO 21 CFR PART 803 BASED ON INFORMATION MADE AVAILABLE TO HOLOGIC THROUGH LITIGATION. CONSISTENT WITH 21 CFR 803.16, THE SUBMISSION OF THIS REPORT IS NOT INTENDED, AND SHALL NOT BE CONSTRUED, AS AN ADMISSION, ACKNOWLEDGMENT, OR CONFIRMATION BY HOLOGIC THAT THE DEVICE CAUSED OR CONTRIBUTED TO THE REPORTABLE EVENT.

  Patient problems: Breast Discomfort/Pain; Breast Mass; Scar Tissue; Seroma

  MAUDE report 24608095 ↗
• InjuryMar 16, 2026Adverse Event Without Identified Device or Use Problem

  HOLOGIC HAS RECEIVED CORRESPONDENCE ARISING FROM LITIGATION. THE LITIGATION ALLEGES THAT A PATIENT UNDERWENT A LEFT BREAST LUMPECTOMY WITH BIOZORB PLACEMENT ON (B)(6) 2019. IT IS ALLEGED THAT THE PATIENT "EXPERIENCED POSTOPERATIVE WOUND-HEALING COMPLICATIONS, INCLUDING A SKIN REACTION TO METHYLENE BLUE WITH A FOCAL AREA OF SKIN NECROSIS, WHICH REQUIRED OFFICE DEBRIDEMENT. DUE TO THESE WOUND ISSUES, HER PLANNED RADIATION THERAPY WAS DELAYED." IT IS FURTHER ALLEGED THAT ON (B)(6) 2019, THE PATIENT WAS "FOUND TO HAVE PARTIAL EXPOSURE OF A FOREIGN BODY AT THE SURGICAL SITE, IDENTIFIED AS THE PREVIOUSLY IMPLANTED BIOZORB MARKER." IT IS REPORTED THAT THE BIOZORB DEVICE WAS REMOVED ON (B)(6) 2019. THIS REPORT IS BEING SUBMITTED PURSUANT TO 21 CFR PART 803 BASED ON INFORMATION MADE AVAILABLE TO HOLOGIC THROUGH LITIGATION. CONSISTENT WITH 21 CFR 803.16, THE SUBMISSION OF THIS REPORT IS NOT INTENDED, AND SHALL NOT BE CONSTRUED, AS AN ADMISSION, ACKNOWLEDGMENT, OR CONFIRMATION BY HOLOGIC THAT THE DEVICE CAUSED.

  Patient problems: Erosion; Impaired Healing; Necrosis

  MAUDE report 24607089 ↗
• InjuryMar 16, 2026Adverse Event Without Identified Device or Use Problem

  HOLOGIC HAS RECEIVED CORRESPONDENCE ARISING FROM LITIGATION. THE LITIGATION ALLEGES THAT A PATIENT UNDERWENT A LEFT BREAST LUMPECTOMY WITH A BIOZORB IMPLANT ON (B)(6) 2023. IT IS ALLEGED THAT IN THE MONTHS FOLLOWING SURGERY, THE PATIENT EXPERIENCED PERSISTENT PAIN AND SWELLING AT THE LUMPECTOMY SITE. IT IS ALLEGED THAT ON (B)(6) 2024, THE AREA SHOWED ERYTHEMA AND WAS "MILDLY SWOLLEN." IN (B)(6) 2025, IT IS ALLEGED THAT THE PATIENT PRESENTED WITH "AN UNUSUAL NON-HEALING WOUND AND DRAINAGE AT THE PRIOR LUMPECTOMY SITE." IT IS ALLEGED THAT "THE DEVICE WAS NOTED TO HAVE ERODED THROUGH THE BREAST TISSUE." ON (B)(6) 2025, IT IS ALLEGED THAT THE PATIENT WAS ADMITTED FOR REMOVAL "OF A LEFT BREAST FOREIGN BODY AND PLACEMENT OF A WOUND VACUUM." IT IS REPORTED THAT "OPERATIVE FINDINGS CONFIRMED AN ERODING BIOZORB DEVICE AT THE LUMPECTOMY SITE, WITH EXCISION OF THE REMAINING BIOZORB MATERIAL AND THE SURROUNDING SCAR CAVITY." THIS REPORT IS BEING SUBMITTED PURSUANT TO 21 CFR PART 803 BASED ON INFORMATION MADE AVAILABLE TO HOLOGIC THROUGH LITIGATION. CONSISTENT WITH 21 CFR 803.16, THE SUBMISSION OF THIS REPORT IS NOT INTENDED, AND SHALL NOT BE CONSTRUED, AS AN ADMISSION, ACKNOWLEDGMENT, OR CONFI

  Patient problems: Abnormal scarring; Breast Discomfort/Pain; Erosion; Erythema; Swelling/ Edema

  MAUDE report 24606810 ↗
• InjuryMar 16, 2026Adverse Event Without Identified Device or Use Problem

  HOLOGIC HAS RECEIVED CORRESPONDENCE ARISING FROM LITIGATION. THE LITIGATION ALLEGES A PATIENT RECEIVED A BIOZORB BREAST MARKER ON (B)(6) 2016, WITH A MARGIN RE-EXCISION ON (B)(6), 2016. IT IS ALLEGED THAT IN LATE 2018, THE PATIENT DEVELOPED "RIGHT BREAST PAIN AND PALPABLE LUMPS IN THE UPPER OUTER QUADRANT," AND "IMAGING AT THAT TIME SHOWED POST-SURGICAL CHANGES AND WAS INTERPRETED AS BENIGN." IT IS FURTHER ALLEGED THAT IN (B)(6) 2023, THE PATIENT EXPERIENCED AN "INFLAMMATORY EVENT INVOLVING THE RIGHT BREAST," AND "PRESENTED WITH SIGNIFICANT PAIN, ERYTHEMA, EDEMA, AND FEVER UP TO 102 DEGREES, AND WAS ADMITTED FOR RIGHT BREAST CELLULITIS." ADDITIONALLY, IT IS REPORTED THAT "CT IMAGING DEMONSTRATED POSTSURGICAL CHANGES, SKIN THICKENING, AND A FLUID COLLECTION CONSISTENT WITH ABSCESS FORMATION." THE PATIENT IS REPORTED TO HAVE "REQUIRED HOSPITALIZATION, INTRAVENOUS ANTIBIOTICS, AND PROLONGED OUTPATIENT TREATMENT." FURTHER, THE LITIGATION ALLEGES THAT THE PATIENT'S "BREAST SYMPTOMS DID NOT FULLY RESOLVE, AND SHE CONTINUED TO REPORT RIGHT BREAST PAIN AND SCARRING ON SUBSEQUENT IMAGING STUDIES. BY EARLY 2025, SCREENING MAMMOGRAPHY AGAIN REQUIRED ADDITIONAL IMAGING DUE TO ABNORMALITIES AND

  Patient problems: Abnormal scarring; Abscess; Breast Discomfort/Pain; Cellulitis; Erythema; Fever; Inflammation; Swelling/ Edema

  MAUDE report 24605823 ↗
• InjuryMar 16, 2026Adverse Event Without Identified Device or Use Problem

  HOLOGIC HAS RECEIVED CORRESPONDENCE ARISING FROM LITIGATION. THE LITIGATION ALLEGES THAT A PATIENT RECEIVED A BIOZORB IMPLANT POST LUMPECTOMY ON (B)(6) 2022. IT IS ALLEGED THAT THE PATIENT DEVELOPED COMPLICATIONS AT THE LUMPECTOMY SITE, WHICH INCLUDE MASTITIS, ABSCESS, REDNESS, SWELLING, PAIN, CHILLS AND PURULENT DRAINAGE. ADDITIONALLY, IT IS REPORTED THAT THE PATIENT WAS HOSPITALIZED FROM (B)(6) 2025, WITH A DIAGNOSIS OF MASTITIS AND ABSCESS AND UNDERWENT AN INCISION AND DRAINAGE PROCEDURE. IT IS REPORTED THAT "CLIPS FROM THE PRIOR BIOZORB WERE REMOVED DURING THE I&D PROCEDURE." THIS REPORT IS BEING SUBMITTED PURSUANT TO 21 CFR PART 803 BASED ON INFORMATION MADE AVAILABLE TO HOLOGIC THROUGH LITIGATION. CONSISTENT WITH 21 CFR 803.16, THE SUBMISSION OF THIS REPORT IS NOT INTENDED, AND SHALL NOT BE CONSTRUED, AS AN ADMISSION, ACKNOWLEDGMENT, OR CONFIRMATION BY HOLOGIC THAT THE DEVICE CAUSED OR CONTRIBUTED TO THE REPORTABLE EVENT.

  Patient problems: Abscess; Bacterial Infection; Breast Discomfort/Pain; Chills; Erythema; Purulent Discharge; Seroma; Swelling/ Edema

  MAUDE report 24604889 ↗
• InjuryMar 16, 2026Adverse Event Without Identified Device or Use Problem

  HOLOGIC HAS RECEIVED CORRESPONDENCE ARISING FROM LITIGATION. THE LITIGATION ALLEGES THAT A PATIENT RECEIVED A BIOZORB IMPLANT ON (B)(6) 2023, AFTER A PARTIAL MASTECTOMY. IT IS ALLEGED THAT IN EARLY 2024, THE PATIENT DEVELOPED SWELLING, HARDNESS, PAIN, REDNESS AND FLUID ACCUMULATION IN THE BREAST. IT IS FURTHER ALLEGED THAT THE PATIENT WAS TREATED WITH MASSAGE THERAPY, LYMPHEDEMA TREATMENT, COMPRESSION BRAS AND STEROIDS. ADDITIONALLY, IT IS ALLEGED THAT DUE TO THE BREAST SYMPTOMS, THE PATIENT EXPERIENCED INCREASING ANXIETY. IT IS REPORTED THAT THE PATIENT HAD THE BIOZORB SURGICALLY REMOVED ON (B)(6) 2025. THIS REPORT IS BEING SUBMITTED PURSUANT TO 21 CFR PART 803 BASED ON INFORMATION MADE AVAILABLE TO HOLOGIC THROUGH LITIGATION. CONSISTENT WITH 21 CFR 803.16, THE SUBMISSION OF THIS REPORT IS NOT INTENDED, AND SHALL NOT BE CONSTRUED, AS AN ADMISSION, ACKNOWLEDGMENT, OR CONFIRMATION BY HOLOGIC THAT THE DEVICE CAUSED OR CONTRIBUTED TO THE REPORTABLE EVENT.

  Patient problems: Anxiety; Breast Discomfort/Pain; Erythema; Seroma; Swelling/ Edema

  MAUDE report 24604783 ↗
• InjuryMar 16, 2026Adverse Event Without Identified Device or Use Problem

  HOLOGIC HAS RECEIVED CORRESPONDENCE ARISING FROM LITIGATION. THE LITIGATION ALLEGES THAT POST RIGHT BREAST LUMPECTOMY ON (B)(6) 2019, A PATIENT RECEIVED A BIOZORB DEVICE IMPLANT. IT IS ALLEGED THAT THE PATIENT HAS SUBSEQUENTLY EXPERIENCED PERSISTENT TENDERNESS AND DISCOMFORT AT THE LUMPECTOMY SITE AS WELL AS SEROMA, SCAR TISSUE AND PALPABLE MASS IN THE REGION OF THE BIOZORB. IT IS FURTHER ALLEGED THAT THE PATIENT EXPERIENCED WORSENING PAIN AND ERYTHEMA AND WAS TREATED WITH ANTIBIOTICS. IT IS ALLEGED THAT ON (B)(6) 2025, THE PATIENT UNDERWENT SURGICAL EXCISION OF THE MASS, WHICH INCLUDED EXPLANTATION OF THE BIOZORB AND REMOVAL OF SURROUNDING NECROTIC TISSUE. THIS REPORT IS BEING SUBMITTED PURSUANT TO 21 CFR PART 803 BASED ON INFORMATION MADE AVAILABLE TO HOLOGIC THROUGH LITIGATION. CONSISTENT WITH 21 CFR 803.16, THE SUBMISSION OF THIS REPORT IS NOT INTENDED, AND SHALL NOT BE CONSTRUED, AS AN ADMISSION, ACKNOWLEDGMENT, OR CONFIRMATION BY HOLOGIC THAT THE DEVICE CAUSED OR CONTRIBUTED TO THE REPORTABLE EV.

  Patient problems: Breast Discomfort/Pain; Breast Mass; Erythema; Inflammation; Necrosis; Scar Tissue; Seroma

  MAUDE report 24604641 ↗
• InjuryMar 16, 2026Adverse Event Without Identified Device or Use Problem

  HOLOGIC HAS RECEIVED CORRESPONDENCE ARISING FROM LITIGATION. THE LITIGATION ALLEGES THAT A PATIENT RECEIVED A BIOZORB IMPLANT POST LUMPECTOMY PROCEDURE ON (B)(6) 2021. IT IS ALLEGED THAT THE PATIENT HAS EXPERIENCED CHRONIC PAIN AND TENDERNESS AT THE LUMPECTOMY SITE IN ADDITION TO A PALPABLE MASS. IT IS ALLEGED THAT DUE TO ONGOING PAIN, TENDERNESS AND PALPABLE MASS, THE BIOZORB IMPLANT WAS REMOVED ON (B)(6) 2025. THIS REPORT IS BEING SUBMITTED PURSUANT TO 21 CFR PART 803 BASED ON INFORMATION MADE AVAILABLE TO HOLOGIC THROUGH LITIGATION. CONSISTENT WITH 21 CFR 803.16, THE SUBMISSION OF THIS REPORT IS NOT INTENDED, AND SHALL NOT BE CONSTRUED, AS AN ADMISSION, ACKNOWLEDGMENT, OR CONFIRMATION BY HOLOGIC THAT THE DEVICE CAUSED OR CONTRIBUTED TO THE REPORTABLE EVENT.

  Patient problems: Anxiety; Breast Discomfort/Pain; Breast Mass

  MAUDE report 24604434 ↗

Other Hologic, Inc. products

• Selenia Dimensions9 models · 245 reports · 3 recalls
• NovaSure5 models · 344 reports
• Brevera Breast Biopsy System5 models · 300 reports
• 3Dimensions9 models · 67 reports · 3 recalls
• Aptima15 models · 82 reports · 2 recalls
• NovaSure SureSound2 models · 182 reports
• Panther Fusion3 models · 9 reports · 3 recalls
• Sertera Biopsy Device2 models · 16 reports · 2 recalls